Industry Research Reports

Home > Reports > Chemical & Material > Global Enflurane Market Outlook, In‑Depth Analysis & Forecast to 2031

Global Enflurane Market Outlook, In‑Depth Analysis & Forecast to 2031

Industry: Chemical & Material

Published Date: 2025-10-26

Pages: 158 Pages

Report ld: 5282568

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Enflurane market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Enflurane is an inhalational anesthetic, belonging to the class of halogenated ethers. It works by inhibiting the central nervous system, rendering patients pain-free and unconscious during surgical procedures. Enflurane is characterized by its rapid onset, strong controllability, and minimal impact on the respiratory and circulatory systems. It is widely used in clinical anesthesia. The market for Enflurane is primarily concentrated in medical institutions and operating rooms. With the advancement of medical technology and the increase in surgical procedures, the demand for Enflurane is also evolving. In recent years, the market share of Enflurane has declined due to the emergence of newer anesthetics. However, it still holds irreplaceable value in specific surgical scenarios. From an industry perspective, the research and development of Enflurane involve not only its pharmacological properties but also its market positioning, competitive landscape, and future development trends.

Market Development Opportunities & Main Driving Factors

The market development opportunities for Enflurane are mainly reflected in several aspects. Firstly, with the increasing global aging population and the growing number of chronic disease patients, the demand for surgeries is also rising, providing a stable market base for Enflurane. Secondly, despite the emergence of new anesthetics, Enflurane still has unique advantages in certain specific surgical scenarios, such as short-duration surgeries and surgeries with lower requirements for respiratory depression. Additionally, the continuous improvement of medical infrastructure and increasing investment in medical resources in developing countries offer new space for the market expansion of Enflurane. These factors collectively drive the continuous development of the Enflurane market.

Market Challenges, Risks, & Restraints

The market for Enflurane also faces numerous challenges and risks. On the one hand, the continuous introduction of new anesthetics has impacted the market share of Enflurane. These new anesthetics may have advantages in terms of safety and side effect control, leading some medical institutions to reduce their use of Enflurane. On the other hand, strict pharmaceutical regulatory policies and environmental requirements have increased the production costs and market access difficulties for Enflurane. Moreover, with intense market competition, companies need to continuously improve their competitiveness in product quality, price, and service to cope with pressure from domestic and international peers.

Downstream Demand Trends

From the perspective of downstream demand trends, the market demand for Enflurane will gradually shift towards refinement and specialization. As medical technology advances and the complexity and precision requirements of surgeries increase, medical institutions will place greater emphasis on the adaptability and safety of anesthetics. In the future, Enflurane is likely to be used more in specific types of surgeries, such as those for elderly patients or in certain specialized departments. Meanwhile, with the development of medical informatization, medical institutions will have more standardized and transparent procurement and usage management of anesthetics, which will also pose higher requirements for the market promotion of Enflurane.

Report Includes:

This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Enflurane market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Baxter
J&TEC
GE Healthcare
Gasera
Draeger
Abbott
AstraZeneca
Sanofi
Pfizer
Johnson & Johnson
Merck
Roche
Novartis

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Pharmaceutical Grade Enflurane
Industrial Grade Enflurane

Segment by Application

Medicine
Chemical Industry
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Enflurane study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.

Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.

Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.

Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.

Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.

Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.

Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.

Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.

Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles

Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.

Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.

Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 15: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:

Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Enflurane: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Enflurane Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Pharmaceutical Grade Enflurane

1.2.3 Industrial Grade Enflurane

1.3 Market Segmentation by Application

1.3.1 Global Enflurane Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Medicine

1.3.3 Chemical Industry

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Enflurane Revenue Estimates and Forecasts 2020-2031

2.2 Global Enflurane Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Enflurane Sales Estimates and Forecasts 2020-2031

2.4 Global Enflurane Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Global Production Analysis

3.1 Global Enflurane Production Capacity and Utilization Rates (2020–2031)

3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)

3.3 Regional Production Dynamics

3.3.1 Historic Production by Region (2020-2025)

3.3.2 Forecasted Production by Region (2026-2031)

3.3.3 Production Market Share by Region (2020-2031)

3.3.4 Regulatory and Trade Policy Impact on Production

3.3.5 Production Capacity Enablers and Constraints

3.4 Key Regional Production Hubs

3.4.1 United States

3.4.2 China

3.4.3 Japan

3.4.4 Germany

3.4.5 India

4 Competition by Manufacturers

4.1 Global Enflurane Sales by Manufacturers

4.1.1 Global Sales Volume by Manufacturers (2020-2025)

4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

4.2 Global Enflurane Manufacturer Revenue Rankings and Tiers

4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

4.3 Manufacturer Profitability Profiles and Pricing Strategies

4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

4.3.2 Manufacturer-Level Price Trends (2020-2025)

4.4 Key Manufacturers Manufacturing Base and Headquarters

4.5 Main Product Type Market Size by Manufacturers

4.5.1 Pharmaceutical Grade Enflurane Market Size by Manufacturers

4.5.2 Industrial Grade Enflurane Market Size by Manufacturers

4.6 Global Enflurane Market Concentration and Dynamics

4.6.1 Global Market Concentration (CR5 and HHI)

4.6.2 Entrant/Exit Impact Analysis

4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

5 Global Product Segmentation Analysis

5.1 Global Enflurane Sales Performance by Type

5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

5.1.2 Global Sales Market Share by Type (2020-2031)

5.2 Global Enflurane Revenue Trends by Type

5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

5.2.2 Global Revenue Market Share by Type (2020-2031)

5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

5.4 Product Technology Differentiation

5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

5.5.1 High-Growth Niches and Adoption Drivers

5.5.2 Profitability Hotspots and Cost Drivers

5.5.3 Substitution Threats

6 Global Downstream Application Analysis

6.1 Global Enflurane Sales by Application

6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

6.1.2 Global Sales Market Share by Application (2020-2031)

6.1.3 High-Growth Application Identification

6.1.4 Emerging Application Case Studies

6.2 Global Enflurane Revenue by Application

6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

6.2.2 Revenue Market Share by Application (2020-2031)

6.3 Global Pricing Dynamics by Application (2020-2031)

6.4 Downstream Customer Analysis

6.4.1 Top Customers by Region

6.4.2 Top Customers by Application

7 North America

7.1 North America Sales Volume and Revenue (2020-2031)

7.2 North America Key Manufacturers Sales Revenue in 2024

7.3 North America Enflurane Sales and Revenue by Type (2020-2031)

7.4 North America Enflurane Sales and Revenue by Application (2020-2031)

7.5 North America Growth Accelerators and Market Barriers

7.6 North America Enflurane Market Size by Country

7.6.1 North America Revenue by Country

7.6.2 North America Sales Trends by Country

7.6.3 US

7.6.4 Canada

7.6.5 Mexico

8 Europe

8.1 Europe Sales Volume and Revenue (2020-2031)

8.2 Europe Key Manufacturers Sales Revenue in 2024

8.3 Europe Enflurane Sales and Revenue by Type (2020-2031)

8.4 Europe Enflurane Sales and Revenue by Application (2020-2031)

8.5 Europe Growth Accelerators and Market Barriers

8.6 Europe Enflurane Market Size by Country

8.6.1 Europe Revenue by Country

8.6.2 Europe Sales Trends by Country

8.6.3 Germany

8.6.4 France

8.6.5 U.K.

8.6.6 Italy

8.6.7 Russia

9 Asia-Pacific

9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

9.3 Asia-Pacific Enflurane Sales and Revenue by Type (2020-2031)

9.4 Asia-Pacific Enflurane Sales and Revenue by Application (2020-2031)

9.5 Asia-Pacific Enflurane Market Size by Region

9.5.1 Asia-Pacific Revenue by Region

9.5.2 Asia-Pacific Sales Trends by Region

9.6 Asia-Pacific Growth Accelerators and Market Barriers

9.7 Southeast Asia

9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand

9.8 China

9.9 Japan

9.10 South Korea

9.11 China Taiwan

9.12 India

10 Central and South America

10.1 Central and South America Sales Volume and Revenue (2020-2031)

10.2 Central and South America Key Manufacturers Sales Revenue in 2024

10.3 Central and South America Enflurane Sales and Revenue by Type (2020-2031)

10.4 Central and South America Enflurane Sales and Revenue by Application (2020-2031)

10.5 Central and South America Investment Opportunities and Key Challenges

10.6 Central and South America Enflurane Market Size by Country

10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 Brazil

10.6.3 Argentina

11 Middle East and Africa

11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

11.3 Middle East and Africa Enflurane Sales and Revenue by Type (2020-2031)

11.4 Middle East and Africa Enflurane Sales and Revenue by Application (2020-2031)

11.5 Middle East and Africa Investment Opportunities and Key Challenges

11.6 Middle East and Africa Enflurane Market Size by Country

11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

11.6.2 GCC Countries

11.6.3 Turkey

11.6.4 Egypt

11.6.5 South Africa

12 Corporate Profile

12.1 Baxter

12.1.1 Baxter Corporation Information

12.1.2 Baxter Business Overview

12.1.3 Baxter Enflurane Product Models, Descriptions and Specifications

12.1.4 Baxter Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.1.5 Baxter Enflurane Sales by Product in 2024

12.1.6 Baxter Enflurane Sales by Application in 2024

12.1.7 Baxter Enflurane Sales by Geographic Area in 2024

12.1.8 Baxter Enflurane SWOT Analysis

12.1.9 Baxter Recent Developments

12.2 J&TEC

12.2.1 J&TEC Corporation Information

12.2.2 J&TEC Business Overview

12.2.3 J&TEC Enflurane Product Models, Descriptions and Specifications

12.2.4 J&TEC Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.2.5 J&TEC Enflurane Sales by Product in 2024

12.2.6 J&TEC Enflurane Sales by Application in 2024

12.2.7 J&TEC Enflurane Sales by Geographic Area in 2024

12.2.8 J&TEC Enflurane SWOT Analysis

12.2.9 J&TEC Recent Developments

12.3 GE Healthcare

12.3.1 GE Healthcare Corporation Information

12.3.2 GE Healthcare Business Overview

12.3.3 GE Healthcare Enflurane Product Models, Descriptions and Specifications

12.3.4 GE Healthcare Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.3.5 GE Healthcare Enflurane Sales by Product in 2024

12.3.6 GE Healthcare Enflurane Sales by Application in 2024

12.3.7 GE Healthcare Enflurane Sales by Geographic Area in 2024

12.3.8 GE Healthcare Enflurane SWOT Analysis

12.3.9 GE Healthcare Recent Developments

12.4 Gasera

12.4.1 Gasera Corporation Information

12.4.2 Gasera Business Overview

12.4.3 Gasera Enflurane Product Models, Descriptions and Specifications

12.4.4 Gasera Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.4.5 Gasera Enflurane Sales by Product in 2024

12.4.6 Gasera Enflurane Sales by Application in 2024

12.4.7 Gasera Enflurane Sales by Geographic Area in 2024

12.4.8 Gasera Enflurane SWOT Analysis

12.4.9 Gasera Recent Developments

12.5 Draeger

12.5.1 Draeger Corporation Information

12.5.2 Draeger Business Overview

12.5.3 Draeger Enflurane Product Models, Descriptions and Specifications

12.5.4 Draeger Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.5.5 Draeger Enflurane Sales by Product in 2024

12.5.6 Draeger Enflurane Sales by Application in 2024

12.5.7 Draeger Enflurane Sales by Geographic Area in 2024

12.5.8 Draeger Enflurane SWOT Analysis

12.5.9 Draeger Recent Developments

12.6 Abbott

12.6.1 Abbott Corporation Information

12.6.2 Abbott Business Overview

12.6.3 Abbott Enflurane Product Models, Descriptions and Specifications

12.6.4 Abbott Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.6.5 Abbott Recent Developments

12.7 AstraZeneca

12.7.1 AstraZeneca Corporation Information

12.7.2 AstraZeneca Business Overview

12.7.3 AstraZeneca Enflurane Product Models, Descriptions and Specifications

12.7.4 AstraZeneca Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.7.5 AstraZeneca Recent Developments

12.8 Sanofi

12.8.1 Sanofi Corporation Information

12.8.2 Sanofi Business Overview

12.8.3 Sanofi Enflurane Product Models, Descriptions and Specifications

12.8.4 Sanofi Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.8.5 Sanofi Recent Developments

12.9 Pfizer

12.9.1 Pfizer Corporation Information

12.9.2 Pfizer Business Overview

12.9.3 Pfizer Enflurane Product Models, Descriptions and Specifications

12.9.4 Pfizer Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.9.5 Pfizer Recent Developments

12.10 Johnson & Johnson

12.10.1 Johnson & Johnson Corporation Information

12.10.2 Johnson & Johnson Business Overview

12.10.3 Johnson & Johnson Enflurane Product Models, Descriptions and Specifications

12.10.4 Johnson & Johnson Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.10.5 Johnson & Johnson Recent Developments

12.11 Merck

12.11.1 Merck Corporation Information

12.11.2 Merck Business Overview

12.11.3 Merck Enflurane Product Models, Descriptions and Specifications

12.11.4 Merck Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.11.5 Merck Recent Developments

12.12 Roche

12.12.1 Roche Corporation Information

12.12.2 Roche Business Overview

12.12.3 Roche Enflurane Product Models, Descriptions and Specifications

12.12.4 Roche Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.12.5 Roche Recent Developments

12.13 Novartis

12.13.1 Novartis Corporation Information

12.13.2 Novartis Business Overview

12.13.3 Novartis Enflurane Product Models, Descriptions and Specifications

12.13.4 Novartis Enflurane Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.13.5 Novartis Recent Developments

13 Value Chain and Supply-Chain Analysis

13.1 Enflurane Industry Chain

13.2 Enflurane Upstream Materials Analysis

13.2.1 Raw Materials

13.2.2 Key Suppliers Market Share & Risk Assessment

13.3 Enflurane Integrated Production Analysis

13.3.1 Manufacturing Footprint Analysis

13.3.2 Production Technology Overview

13.3.3 Regional Cost Drivers

13.4 Enflurane Sales Channels and Distribution Networks

13.4.1 Sales Channels

13.4.2 Distributors

14 Enflurane Market Dynamics

14.1 Industry Trends and Evolution

14.2 Market Growth Drivers and Emerging Opportunities

14.3 Market Challenges, Risks, and Restraints

15 Key Findings in the Global Enflurane Study

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.1.1 Research Programs/Design

16.1.1.2 Market Size Estimation

16.1.1.3 Market Breakdown and Data Triangulation

16.1.2 Data Source

16.1.2.1 Secondary Sources

16.1.2.2 Primary Sources

16.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Enflurane Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Enflurane Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Enflurane Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Enflurane Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Enflurane Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Enflurane Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (MT)

Table 7. Global Enflurane Sales by Region (2020-2025) & (MT)

Table 8. Global Enflurane Sales by Region (2026-2031) & (MT)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Enflurane Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (MT)

Table 11. Global Enflurane Production by Region (2020-2025) & (MT)

Table 12. Global Enflurane Production by Region (2026-2031) & (MT)

Table 13. Global Enflurane Sales by Manufacturers (2020-2025) & (MT)

Table 14. Global Enflurane Sales Share by Manufacturers (2020-2025)

Table 15. Global Enflurane Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 16. Global Enflurane Revenue Market Share by Manufacturers (2020-2025)

Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 18. Global Enflurane by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enflurane as of 2024)

Table 19. Global Enflurane Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 20. Global Enflurane Average Selling Price (ASP) by Manufacturers (2020-2025) & (USD/MT)

Table 21. Key Manufacturers Enflurane Manufacturing Base and Headquarters

Table 22. Global Enflurane Market Concentration Ratio (CR5 and HHI)

Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 25. Global Enflurane Sales by Type (2020-2025) & (MT)

Table 26. Global Enflurane Sales by Type (2026-2031) & (MT)

Table 27. Global Enflurane Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Enflurane Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Enflurane ASP by Type (2020-2031) & (USD/MT)

Table 30. Technical Specifications by Key Product Type

Table 31. Global Enflurane Sales by Application (2020-2025) & (MT)

Table 32. Global Enflurane Sales by Application (2026-2031) & (MT)

Table 33. Enflurane High-Growth Sectors Demand CAGR (2024-2031)

Table 34. Global Enflurane Revenue by Application (2020-2025) & (US$ Million)

Table 35. Global Enflurane Revenue by Application (2026-2031) & (US$ Million)

Table 36. Global Enflurane ASP by Application (2020-2031) & (USD/MT)

Table 37. Top Customers by Region

Table 38. Top Customers by Application

Table 39. North America Enflurane Growth Accelerators and Market Barriers

Table 40. North America Enflurane Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 41. North America Enflurane Sales (MT) by Country (2020 VS 2024 VS 2031)

Table 42. Europe Enflurane Growth Accelerators and Market Barriers

Table 43. Europe Enflurane Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 44. Europe Enflurane Sales (MT) by Country (2020 VS 2024 VS 2031)

Table 45. Asia-Pacific Enflurane Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Asia-Pacific Enflurane Sales (MT) by Country (2020 VS 2024 VS 2031)

Table 47. Asia-Pacific Enflurane Growth Accelerators and Market Barriers

Table 48. Southeast Asia Enflurane Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 49. Central and South America Enflurane Investment Opportunities and Key Challenges

Table 50. Central and South America Enflurane Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 51. Middle East and Africa Enflurane Investment Opportunities and Key Challenges

Table 52. Middle East and Africa Enflurane Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 53. Baxter Corporation Information

Table 54. Baxter Description and Major Businesses

Table 55. Baxter Product Models, Descriptions and Specifications

Table 56. Baxter Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 57. Baxter Sales Value Proportion by Product in 2024

Table 58. Baxter Sales Value Proportion by Application in 2024

Table 59. Baxter Sales Value Proportion by Geographic Area in 2024

Table 60. Baxter Enflurane SWOT Analysis

Table 61. Baxter Recent Developments

Table 62. J&TEC Corporation Information

Table 63. J&TEC Description and Major Businesses

Table 64. J&TEC Product Models, Descriptions and Specifications

Table 65. J&TEC Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 66. J&TEC Sales Value Proportion by Product in 2024

Table 67. J&TEC Sales Value Proportion by Application in 2024

Table 68. J&TEC Sales Value Proportion by Geographic Area in 2024

Table 69. J&TEC Enflurane SWOT Analysis

Table 70. J&TEC Recent Developments

Table 71. GE Healthcare Corporation Information

Table 72. GE Healthcare Description and Major Businesses

Table 73. GE Healthcare Product Models, Descriptions and Specifications

Table 74. GE Healthcare Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 75. GE Healthcare Sales Value Proportion by Product in 2024

Table 76. GE Healthcare Sales Value Proportion by Application in 2024

Table 77. GE Healthcare Sales Value Proportion by Geographic Area in 2024

Table 78. GE Healthcare Enflurane SWOT Analysis

Table 79. GE Healthcare Recent Developments

Table 80. Gasera Corporation Information

Table 81. Gasera Description and Major Businesses

Table 82. Gasera Product Models, Descriptions and Specifications

Table 83. Gasera Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 84. Gasera Sales Value Proportion by Product in 2024

Table 85. Gasera Sales Value Proportion by Application in 2024

Table 86. Gasera Sales Value Proportion by Geographic Area in 2024

Table 87. Gasera Enflurane SWOT Analysis

Table 88. Gasera Recent Developments

Table 89. Draeger Corporation Information

Table 90. Draeger Description and Major Businesses

Table 91. Draeger Product Models, Descriptions and Specifications

Table 92. Draeger Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 93. Draeger Sales Value Proportion by Product in 2024

Table 94. Draeger Sales Value Proportion by Application in 2024

Table 95. Draeger Sales Value Proportion by Geographic Area in 2024

Table 96. Draeger Enflurane SWOT Analysis

Table 97. Draeger Recent Developments

Table 98. Abbott Corporation Information

Table 99. Abbott Description and Major Businesses

Table 100. Abbott Product Models, Descriptions and Specifications

Table 101. Abbott Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 102. Abbott Recent Developments

Table 103. AstraZeneca Corporation Information

Table 104. AstraZeneca Description and Major Businesses

Table 105. AstraZeneca Product Models, Descriptions and Specifications

Table 106. AstraZeneca Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 107. AstraZeneca Recent Developments

Table 108. Sanofi Corporation Information

Table 109. Sanofi Description and Major Businesses

Table 110. Sanofi Product Models, Descriptions and Specifications

Table 111. Sanofi Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 112. Sanofi Recent Developments

Table 113. Pfizer Corporation Information

Table 114. Pfizer Description and Major Businesses

Table 115. Pfizer Product Models, Descriptions and Specifications

Table 116. Pfizer Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 117. Pfizer Recent Developments

Table 118. Johnson & Johnson Corporation Information

Table 119. Johnson & Johnson Description and Major Businesses

Table 120. Johnson & Johnson Product Models, Descriptions and Specifications

Table 121. Johnson & Johnson Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 122. Johnson & Johnson Recent Developments

Table 123. Merck Corporation Information

Table 124. Merck Description and Major Businesses

Table 125. Merck Product Models, Descriptions and Specifications

Table 126. Merck Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 127. Merck Recent Developments

Table 128. Roche Corporation Information

Table 129. Roche Description and Major Businesses

Table 130. Roche Product Models, Descriptions and Specifications

Table 131. Roche Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 132. Roche Recent Developments

Table 133. Novartis Corporation Information

Table 134. Novartis Description and Major Businesses

Table 135. Novartis Product Models, Descriptions and Specifications

Table 136. Novartis Capacity, Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 137. Novartis Recent Developments

Table 138. Key Raw Materials Distribution

Table 139. Raw Materials Key Suppliers

Table 140. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 141. Milestones in Production Technology Evolution

Table 142. Distributors List

Table 143. Market Trends and Market Evolution

Table 144. Market Drivers and Opportunities

Table 145. Market Challenges, Risks, and Restraints

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

List of Figures

Figure 1. Enflurane Product Picture

Figure 2. Global Enflurane Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Pharmaceutical Grade Enflurane Product Picture

Figure 4. Industrial Grade Enflurane Product Picture

Figure 5. Global Enflurane Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Medicine

Figure 7. Chemical Industry

Figure 8. Others

Figure 9. Enflurane Report Years Considered

Figure 10. Global Enflurane Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Enflurane Revenue (2020-2031) & (US$ Million)

Figure 12. Global Enflurane Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Enflurane Revenue Market Share by Region (2020-2031)

Figure 14. Global Enflurane Sales (2020-2031) & (MT)

Figure 15. Global Enflurane Sales (CAGR) by Region (2020-2031) (MT)

Figure 16. Global Enflurane Sales Market Share by Region (2020-2031)

Figure 17. Global Enflurane Capacity, Production and Utilization (2020-2031) & (MT)

Figure 18. Global Enflurane Production Trend by Region (2020-2031) (MT)

Figure 19. Global Enflurane Production Market Share by Region (2020-2031)

Figure 20. Production Capacity Enablers & Constraints

Figure 21. Enflurane Production Growth Rate in United States (2020-2031) & (MT)

Figure 22. Enflurane Production Growth Rate in China (2020-2031) & (MT)

Figure 23. Enflurane Production Growth Rate in Japan (2020-2031) & (MT)

Figure 24. Enflurane Production Growth Rate in Germany (2020-2031) & (MT)

Figure 25. Enflurane Production Growth Rate in India (2020-2031) & (MT)

Figure 26. Top 5 and Top 10 Manufacturers Enflurane Sales Volume Market Share in 2024

Figure 27. Global Enflurane Revenue Market Share Ranking (2024)

Figure 28. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 29. Pharmaceutical Grade Enflurane Revenue Market Share by Manufacturer in 2024

Figure 30. Industrial Grade Enflurane Revenue Market Share by Manufacturer in 2024

Figure 31. Type Eight Revenue Market Share by Manufacturer in 2024

Figure 32. Type Nine Revenue Market Share by Manufacturer in 2024

Figure 33. Global Enflurane Sales Market Share by Type (2020-2031)

Figure 34. Global Enflurane Revenue Market Share by Type (2020-2031)

Figure 35. Global Enflurane Sales Market Share by Application (2020-2031)

Figure 36. Global Enflurane Revenue Market Share by Application (2020-2031)

Figure 37. North America Enflurane Sales YoY (2020-2031) & (MT)

Figure 38. North America Enflurane Revenue YoY (2020-2031) & (US$ Million)

Figure 39. North America Top 5 Manufacturers Enflurane Sales Revenue (US$ Million) in 2024

Figure 40. North America Enflurane Sales Volume (MT) by Type (2020- 2031)

Figure 41. North America Enflurane Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 42. North America Enflurane Sales Volume (MT) by Application (2020-2031)

Figure 43. North America Enflurane Sales Revenue (US$ Million) by Application (2020-2031)

Figure 44. US Enflurane Revenue (2020-2031) & (US$ Million)

Figure 45. Canada Enflurane Revenue (2020-2031) & (US$ Million)

Figure 46. Mexico Enflurane Revenue (2020-2031) & (US$ Million)

Figure 47. Europe Enflurane Sales YoY (2020-2031) & (MT)

Figure 48. Europe Enflurane Revenue YoY (2020-2031) & (US$ Million)

Figure 49. Europe Top 5 Manufacturers Enflurane Sales Revenue (US$ Million) in 2024

Figure 50. Europe Enflurane Sales Volume (MT) by Type (2020-2031)

Figure 51. Europe Enflurane Sales Revenue (US$ Million) by Type (2020-2031)

Figure 52. Europe Enflurane Sales Volume (MT) by Application (2020-2031)

Figure 53. Europe Enflurane Sales Revenue (US$ Million) by Application (2020-2031)

Figure 54. Germany Enflurane Revenue (2020-2031) & (US$ Million)

Figure 55. France Enflurane Revenue (2020-2031) & (US$ Million)

Figure 56. U.K. Enflurane Revenue (2020-2031) & (US$ Million)

Figure 57. Italy Enflurane Revenue (2020-2031) & (US$ Million)

Figure 58. Russia Enflurane Revenue (2020-2031) & (US$ Million)

Figure 59. Asia-Pacific Enflurane Sales YoY (2020-2031) & (MT)

Figure 60. Asia-Pacific Enflurane Revenue YoY (2020-2031) & (US$ Million)

Figure 61. Asia-Pacific Top 8 Manufacturers Enflurane Sales Revenue (US$ Million) in 2024

Figure 62. Asia-Pacific Enflurane Sales Volume (MT) by Type (2020- 2031)

Figure 63. Asia-Pacific Enflurane Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 64. Asia-Pacific Enflurane Sales Volume (MT) by Application (2020-2031)

Figure 65. Asia-Pacific Enflurane Sales Revenue (US$ Million) by Application (2020-2031)

Figure 66. Indonesia Enflurane Revenue (2020-2031) & (US$ Million)

Figure 67. Japan Enflurane Revenue (2020-2031) & (US$ Million)

Figure 68. South Korea Enflurane Revenue (2020-2031) & (US$ Million)

Figure 69. China Taiwan Enflurane Revenue (2020-2031) & (US$ Million)

Figure 70. India Enflurane Revenue (2020-2031) & (US$ Million)

Figure 71. Central and South America Enflurane Sales YoY (2020-2031) & (MT)

Figure 72. Central and South America Enflurane Revenue YoY (2020-2031) & (US$ Million)

Figure 73. Central and South America Top 5 Manufacturers Enflurane Sales Revenue (US$ Million) in 2024

Figure 74. Central and South America Enflurane Sales Volume (MT) by Type (2021-2031)

Figure 75. Central and South America Enflurane Sales Revenue (US$ Million) by Type (2020-2031)

Figure 76. Central and South America Enflurane Sales Volume (MT) by Application (2020-2031)

Figure 77. Central and South America Enflurane Sales Revenue (US$ Million) by Application (2020-2031)

Figure 78. Brazil Enflurane Revenue (2020-2025) & (US$ Million)

Figure 79. Argentina Enflurane Revenue (2020-2025) & (US$ Million)

Figure 80. Middle East, and Africa Enflurane Sales YoY (2020-2031) & (MT)

Figure 81. Middle East and Africa Enflurane Revenue YoY (2020-2031) & (US$ Million)

Figure 82. Middle East and Africa Top 5 Manufacturers Enflurane Sales Revenue (US$ Million) in 2024

Figure 83. Middle East and Africa Enflurane Sales Volume (MT) by Type (2021-2031)

Figure 84. South America Enflurane Sales Revenue (US$ Million) by Type (2020-2031)

Figure 85. Middle East and Africa Enflurane Sales Volume (MT) by Application (2020-2031)

Figure 86. Middle East and Africa Enflurane Sales Revenue (US$ Million) by Application (2020-2031)

Figure 87. GCC Countries Enflurane Revenue (2020-2025) & (US$ Million)

Figure 88. Turkey Enflurane Revenue (2020-2025) & (US$ Million)

Figure 89. Egypt Enflurane Revenue (2020-2025) & (US$ Million)

Figure 90. South Africa Enflurane Revenue (2020-2025) & (US$ Million)

Figure 91. Enflurane Industry Chain Mapping

Figure 92. Regional Enflurane Manufacturing Base Distribution (%)

Figure 93. Enflurane Production Process

Figure 94. Regional Enflurane Production Cost Structure

Figure 95. Channels of Distribution (Direct Vs Distribution)

Figure 96. Bottom-up and Top-down Approaches for This Report

Figure 97. Data Triangulation

Figure 98. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Enflurane market? zhanKai

The top companies in the global Enflurane market are Baxter、J&TEC、GE Healthcare.

Related Reports

Global Enflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Enflurane market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-09
Pages: 94
USD 4250.00
(Single User License)
Global Enflurane Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Enflurane market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-09
Pages: 162
USD 4900.00
(Single User License)
Enflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Enflurane was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-03-05
Pages: 128
USD 3950.00
(Single User License)
Global Enflurane Market Research Report 2026
The global Enflurane market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-03-05
Pages: 137
USD 2900.00
(Single User License)
Global Enflurane Market Insights, Forecast to 2031
The global Enflurane market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
Published Date: 2025-06-16
Pages: 168
USD 4900.00
(Single User License)
Enflurane - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Enflurane was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-06-16
Pages: 111
USD 3950.00
(Single User License)
Global Enflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Enflurane market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-06-16
Pages: 98
USD 4250.00
(Single User License)
Global Enflurane Market Research Report 2025
The global market for Enflurane was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-06-16
Pages: 102
USD 2900.00
(Single User License)
Enflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Enflurane was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-24
Pages: 93
USD 3950.00
(Single User License)
Global Enflurane Market Insights, Forecast to 2030
Enflurane is weaker than diethyl ether, and is generally used in combination with general anesthesia, or in combination with a variety of intravenous general anesthesia and general anesthesia.
Published Date: 2024-04-19
Pages: 97
USD 4900.00
(Single User License)

Global Enflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Enflurane market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-09
Pages: 94
USD 4250.00 (Single User License)
Global Enflurane Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Enflurane market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-09
Pages: 162
USD 4900.00 (Single User License)
Enflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Enflurane was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-03-05
Pages: 128
USD 3950.00 (Single User License)
Global Enflurane Market Research Report 2026
The global Enflurane market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-03-05
Pages: 137
USD 2900.00 (Single User License)
Global Enflurane Market Insights, Forecast to 2031
The global Enflurane market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
Published: 2025-06-16
Pages: 168
USD 4900.00 (Single User License)
Enflurane - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Enflurane was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-06-16
Pages: 111
USD 3950.00 (Single User License)
Global Enflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Enflurane market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-06-16
Pages: 98
USD 4250.00 (Single User License)
Global Enflurane Market Research Report 2025
The global market for Enflurane was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-06-16
Pages: 102
USD 2900.00 (Single User License)
Enflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Enflurane was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-24
Pages: 93
USD 3950.00 (Single User License)
Global Enflurane Market Insights, Forecast to 2030
Enflurane is weaker than diethyl ether, and is generally used in combination with general anesthesia, or in combination with a variety of intravenous general anesthesia and general anesthesia.
Published: 2024-04-19
Pages: 97
USD 4900.00 (Single User License)